XYLOMETAZOLINE

/static/temp/default.svg

Search structure


Synonyms	Balminil Xylometazoline
Status
Molecule Category	Free-form
ATC	R01AA07 R01AB06 S01GA03
UNII	WPY40FTH8K
EPA CompTox	DTXSID8046957


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	HUCJFAOMUPXHDK-UHFFFAOYSA-N
Smiles	Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1
InChI	InChI=1S/C16H24N2/c1-11-8-13(16(3,4)5)9-12(2)14(11)10-15-17-6-7-18-15/h8-9H,6-7,10H2,1-5H3,(H,17,18)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C16H24N2
Molecular Weight	244.38
AlogP	3.15
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	2.0
Polar Surface Area	24.39
Molecular species	BASE
Aromatic Rings	1.0
Heavy Atoms	18.0

Assay Description	Organism	Bioactivity	Reference
Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand	None	14.0 nM
Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV)	Oryctolagus cuniculus	369.0 nM
Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand	None	0.7 nM
Binding affinity towards Alpha-2 adrenergic receptor	None	500.0 nM
Binding affinity towards Alpha-1 adrenergic receptor	Canis lupus familiaris	91.0 nM
Binding affinity against alpha-1 adrenergic receptor is the ability to inhibit the specific [3H]prazosin binding (0.2 nM) to rat isolated brain membranes by 50% was reported; 5.8*10e-7	None	580.0 nM
Binding affinity against Alpha-2 adrenergic receptor is the ability to inhibit the specific [3H]clonidine binding (0.4 nM) to rat isolated brain membranes by 50% was reported; 2.3*10e-8	None	23.0 nM
Binding affinity towards human 5-hydroxytryptamine 1B receptor	Homo sapiens	13.0 nM
Binding affinity towards human 5-hydroxytryptamine 1D receptor	Homo sapiens	0.7 nM
Binding affinity towards human Alpha-1 adrenergic receptor	Homo sapiens	91.0 nM
Displacement of [3H]clonidine from alpha-adrenergic receptor in rat brain	Rattus norvegicus	4.8 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	13.6 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.09 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.09 %

Related Entries

Cross References

Resources	Reference
ChEBI	10082
ChEMBL	CHEMBL312448
DrugBank	DB06694
DrugCentral	3658
FDA SRS	WPY40FTH8K
Human Metabolome Database	HMDB0015640
Guide to Pharmacology	517
KEGG	C07913
PharmGKB	PA165958368
PubChem	5709
SureChEMBL	SCHEMBL34087
ZINC	ZINC000000057534

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).